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Introduction
Kidney transplantation is accepted as the ideal therapy for end-stage renal disease, including in patients with human immunodeficiency virus (HIV) infection; the Solid Organ Transplantation in HIV: Multi-Site Study and registry analyses have demonstrated excellent patient and allograft outcomes for HIV-positive (HIV+) patients who are kidney transplant (KT) recipients (1) (2) (3) (4) . As experience with transplantation in HIV+ patients has grown, significant drug-drug interactions between anti-retroviral therapy (ART) and maintenance immunosuppression have been identified as a major clinical challenge, especially in patients on protease inhibitor (PI)-based regimens (5) .
PIs are metabolized via hepatic cytochrome P450 (CYP) 3A4 (CYP3A4) and are potent inhibitors of CYP3A4 activity; CYP3A4 is also the main enzymatic pathway by which calcineurin inhibitors (CNIs) are metabolized (6) . Coadministration of PIs with CNIs requires significantly decreased CNI doses and prolonged dosing intervals to avoid supratherapeutic trough levels. Frassetto et al. demonstrated that HIV+ solid organ recipients who were being treated with cyclosporine and PI-based ART required a four-to fivefold lower cyclosporine dose with a 50% increase in the dosing interval, whereas those on maintenance tacrolimus and a PI necessitated an 80% tacrolimus dose decrease with a sevenfold increase in dosing interval (7) . Not only does this irregular dosing strategy create burdensome complexity for HIV+ transplant recipients but it also leads to underdosing of CNIs by clinicians. In a pharmacokinetic study by van Maarseveen et al. it was noted that use of ritonavir-based ART resulted in a loss of the tacrolimus absorption peak and a 44% lower area under the curve for tacrolimus exposure in these patients, despite targeting similar trough levels; thus patients on PI regimens need to have higher CNI trough targets than HIV-negative (HIV -recipients to achieve similar CNI exposure (8) . Taken together, this adherence-challenging dosing schedule and unrecognized systemic underdosing of CNIs may in part explain the high incidence of acute rejection observed in the HIV multi-site study, where 52% of patients were treated with PI-based ART (1).
To date, no national study has looked specifically at the impact of ART regimen on posttransplantation patient and allograft outcomes; this is because information regarding anti-retroviral therapy is not collected by the Organ Procurement and Transplantation Network (OPTN) and single-center studies are underpowered to do so. To answer this question we performed a novel linkage of the Scientific Registry of Transplant Recipients (SRTR) and Intercontinental Marketing Services (IMS) pharmacy fills and were able to assess the association between PI-based regimens and HIV+ KT patient and allograft survival.
Methods

Data source
The study used data from the SRTR, which includes data on all donor, wait-listed candidates, and transplant recipients in the United States, submitted by members of the OPTN. The Health Resources and Services Administration of the US Department of Health and Human Services provides the oversight to the activities of the OPTN and SRTR contractors. Because OPTN does not capture anti-retroviral medication data, SRTR was linked with IMS Health, a national data source that collects medication fills through participating pharmacies nationwide, which allowed for capture of pharmaceutical fills for HIV+ KT recipients.
Study population
We identified 535 adult HIV+ KT recipients who underwent transplantation between January 1, 2001, and October 1, 2012, and who filled at least one HIV-specific medication through IMS. Multi-organ recipients and patients prescribed emtricitabine, lamivudine, or tenofovir monotherapy were excluded, as patients who had been prescribed these drugs likely had hepatitis B rather than HIV infection. Recipients were included in the primary analysis if they had both pre-and posttransplantation ART fills (n = 332); those with fill data within 2 years of KT (n = 413) were considered in a secondary sensitivity analysis (Figure 1 ). Recipients were characterized as being on PI-based or non-PI-based regimens according to their ART regimen at the time of transplantation. If there were no fills overlapping with the transplantation date, the closest pretransplantation fill was used.
Outcome ascertainment
The primary outcomes of interest were allograft survival and patient survival. Allograft survival was defined as the time from transplantation to allograft loss, return to dialysis, or death, and was censored for administrative end of study (10/01/2015) . Patient survival was defined as the time from transplantation to death, censored for administrative end of study. The secondary outcome of acute rejection was defined as a recorded episode of acute rejection during follow-up, biopsy-proven acute rejection, allograft failure due to acute rejection, or documented treatment for acute rejection within 1 year of KT. Death dates were supplemented by SRTR linkage to the Social Security Master Death File. Death dates and return to dialysis were supplemented by SRTR linkage to data from the Centers for Medicare & Medicaid Services.
Exploratory data analyses
Recipient and donor characteristics were compared according to ART regimen. Continuous variables were analyzed using Wilcoxon rank-sum tests, and categorical variables were examined using chi-square tests of independence. 
Survival analyses
Unadjusted survival time from transplantation was assessed using Kaplan-Meier curves and compared by ART regimen with the log-rank test. Risk factors for allograft and patient survival were identified using univariate Cox proportional hazards with statistical significance set at p = 0.1 for model inclusion. Beginning with Estimated Post Transplant Survival (EPTS) score, the race, gender, and covariates were added to assess statistical and clinical significance in addition to effect on model fit as measured by the Akaike Information Criteria (AIC). The final models examined risk according to ART regimen and adjusted for recipient EPTS score, race, gender, hepatitis C virus (HCV) status, Kidney Donor Profile Index (KDPI), maintenance and induction immunosuppression regimens as reported to the United Network for Organ Sharing (UNOS), and transplant era. The model for allograft survival also included panel reactive antibody (PRA). Additional models for patient and allograft survival were built containing donor type and the individual components of KDPI; the resulting estimates were compared to our primary models and were consistent. To avoid overfitting, the models containing KDPI are presented. Various functional forms and categorizations of continuous variables were explored for statistical significance and improvement in model fit as measured by the AIC. The proportional hazards assumption was assessed and verified using time-dependent covariates. A robust sandwich estimator was included to account for within-center clustering. Given concerns about early graft loss and acute rejection, we chose to explore the timevarying association of PI regimen with allograft loss. To do so, a splined Cox model was used to generate time-dependent hazard ratios (HRs).
Acute rejection
Risk of acute rejection was assessed using modified Poisson regression (9) . Risk factors for acute rejection were selected using univariate modified Poisson regression with statistical significance set at p = 0.1; furthermore, factors known to be associated with acute rejection were included in the multivariable analyses. The final model examined risk of acute rejection by ART regimen and adjusted for the following: EPTS score, race, gender, HCV status, PRA, donor type, donor HCV status, and maintenance and induction immunosuppression regimens.
Sensitivity analyses
All models were initially built among recipients with complete data. To assess for potential bias introduced by missing data, recipient and donor characteristics were compared between recipients with complete data and those missing data. Models for allograft and patient survival were built with missing data elements coded as "Missing" to allow for inclusion of those recipients in the models. Inferences were consistent with the presented complete case analyses. Given concerns about changes in ART regimen during initial hospitalization for transplantation, additional models were built for patient and graft survival characterizing patients according to ART regimen at discharge or earliest posttransplantation medication fill. Inferences were consistent with those presented. Finally, the models were constructed among a larger cohort of 413 patients who had a fill within 2 years of transplantation. ART regimens were assumed to have remained consistent from last fill date through the duration of the study period. Inferences derived from this larger cohort were consistent with the findings from the cohort of 332. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC) and Stata version 14 (StataCorp, College Station, TX).
Results
Patient and donor characteristics
During the study period, there were 332 HIV+ KT recipients with both pre-and posttransplantation fills identified. Based on the regimen filled on the date of transplantation, 88 (26.5%) received a PI-based regimen (mean follow-up of 4.4 AE 2.7 years), and 244 (73.5%) received a non-PI-based regimen (mean follow-up of 5.1 AE 2.5 years). There was no statistically significant difference in recipient median age (47 vs. 46 years, p = 0.32), race (African American 70.5% vs. 74.2%, p = 0.36), or gender (male 79.6% vs. 78.7%, p = 0.87) based on ART regimen. Recipients who were on a PIbased regimen were more likely to have an EPTS score >20% (70.9% vs. 56.3%, p = 0.02) and longer pretransplantation dialysis duration (6.9 vs. 5.1 years, p = 0.04). The proportion of deceased donors was similar across ART regimens (73.9% vs. 78.7%, p = 0.35), as was the utilization of HCV+ donors (16.9% vs. 15.1%, p = 0.73) and the mean KDPI (32.5 vs. 38, p = 0.37) ( Table 1 ). To elucidate trends in utilization, ART fills were compared pretransplantation, at transplantation, and at 1-year posttransplantation. During study follow up, 23.8% of patients in the PI cohort switched regimens, 66.7% to an integrase inhibitor-based regimen and 33.3% to a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen. Thirty-seven recipients (15.2%) in the non-PI cohort switched to an integrase inhibitor-based regimen in the first-year posttransplantation. As a result, there was a significant decrease in utilization of PI regimens across the three time points (32.2% vs. 22.6%, p < 0.001), whereas receipt of integrase inhibitor-based regimens increased significantly pre-to posttransplantation (6.3% vs. 23.6%, p < 0.001) (Figure 2 ).
Allograft survival
In unadjusted survival analysis, PI-based regimens were associated with lower rates of allograft survival as compared to non-PI regimens (3 years: 79.6% vs. 89.8% p = 0.04) (Figure 3 ). Co-infection with HCV, African American race, deceased donors, HCV+ donors, high KDPI organs, delayed allograft function, and greater HLAmismatches were all associated with an increased risk of allograft loss in unadjusted analyses; use of CNIs was protective (Table 2) . In a multivariable model adjusted for recipient and donor characteristics (Table 3) , PI-based regimens were associated with a 1.8-fold higher risk of allograft loss as compared to non-PI regimens (adjusted HR [aHR] 1.84, 95% confidence interval [CI] 1.22-2.77, p = 0.003), and African American race, male sex, HCV co-infection, and KDPI >20% were all independently associated with allograft loss. CNI maintenance immunosuppression and transplantation in the more recent era (2008-2012), however, were protective (Table 3 ). In sensitivity analyses where we used posttransplantation ART regimens to categorize patients instead of regimen at the time of transplantation, our findings were similar (aHR 1.64, 95% CI 1.16-2.31, p = 0.005; Table S1 ). Models that explored the effect of specific maintenance immunosuppressive regimens (tacrolimus, cyclosporine, or non-CNIs, as well as mycophenolate mofetil vs. azathioprine) yielded similar results and are presented in Table S2 . When we examined the subset of patients who were on tenofovir-based regimens, we did not detect a significant difference in graft survival associated with tenofovir use (aHR 0.74, 95% CI 0.22-2.47, p = 0.63); similarly, we did not detect an effect for raltegravir-based regimens, but the total number of patients was small (n = 39) (Tables S3 and S4 ).
To assess for differential risk of allograft loss by PI regimen over time, the risk of allograft loss associated with PI-based regimens in the first year posttransplantation was allowed to differ from the risk in subsequent years of follow-up. Recipients on PI-based regimens experienced a 4.5-fold higher risk of allograft loss in the first year posttransplantation as compared to those on non-PI regimens (aHR 4.48, 95% CI 1.75-11.48, p = 0.002). After 1 year, the magnitude of the risk associated with PI-based regimens was attenuated with those receiving a PI-based regimen experiencing a non-significant increased risk as compared to non-PI regimens (aHR 1.40, 95% CI 0.84-2.32, p = 0.20) (Table 4) .
Acute rejection
The rate of acute rejection in our cohort was 18.5%, with higher but not statistically significant different rates among recipients on PI-based regimens (20.0% vs. 17.9%, p = 0.67). In a multivariable modified Poisson regression model, there was no statistically significant effect of PI-based regimen on risk of acute rejection, although the estimated effect trended positive (adjusted relative risk: 1.34, 95% CI 0.81-2.24, p = 0.26).
Patient survival
In unadjusted survival analyses, there was a trend toward inferior patient survival for those on PI-regimens compared to non-PI regimens (3 years: 89.8% vs. 96.3%, p = 0.09) (Figure 4 ). Older recipients, those with an EPTS >20%, patients with diabetes, co-infected patients, and recipients of a deceased donor or a high KDPI organ experienced increased risk of death, whereas CNI maintenance immunosuppression was protective ( Table 2) . In a multivariable model that adjusted for recipient and donor characteristics, PI-based regimens were associated with a 1.9-fold increased risk of death (aHR 1.91, 95% CI 1.02-3.59, p = 0.05), and EPTS >20%, co-infection with HCV, and receipt of a high KDPI (>85%) kidney were all independently associated with an increased patient mortality. CNI maintenance immunosuppression was protective, and transplant era did not have a significant effect on patient mortality (Table 5) ; we did not detect a difference in outcomes based on the particular CNI or antimetabolite used (Table S2) . Again, in models that used posttransplantation ART regimens, outcomes were similar (aHR 1.70, 95% CI 1.05-2.74, p = 0.03; Table S1 ). We did not detect a significant effect on patient survival with raltegravir use (aHR 0.80, 95% CI 0.30-2.12, p = 0.65) (Table S5) .
Discussion
In this retrospective analysis of the SRTR database linked to pharmacy data from IMS Health we demonstrate that use of PI-based ART in KT recipients is independently associated with inferior patient and allograft outcomes. The increased risk of allograft failure associated with PIbased regimens was not unexpected. PIs have significant drug-drug interactions with CNIs, which are the current mainstay of maintenance immunosuppression; the need for significant dose reduction and irregular dosing intervals can create challenges to adherence as well as facilitate clinician underdosing of CNIs. These factors together may explain the higher than expected rates of acute rejection observed in series of HIV+ KT from the United States and Europe (1, (10) (11) (12) (13) (14) . In the HIV multi-site study, where >50% of patients were on PI-based ART, the cumulative incidence of rejection was 31% in the first posttransplantation year, compared to an expected rate of 12.3%; in Spain and the United Kingdom the acute rejection rate approaches 40% (13, 14) .
However, the marked decrease in allograft survival was not definitively attributable to an increased risk of acute rejection in PI-treated patients. It is likely that we were insufficiently powered to detect a statistically significant effect of PIs on acute rejection rates in our cohort. PI-based ART, however, seems to contribute to allograft loss by other mechanisms. If drug-drug interactions are not appropriately accounted for by clinicians, too high of CNI trough may be targeted in an attempt to avoid rejection. As a result, patients would then be at risk of CNI toxicity and accelerated allograft failure. In response to drugdosing challenges, and in a reflection of contemporary HIV care, many transplant recipients are now transitioned to integrase inhibitor-based regimens. Integrase inhibitorbased regimens permit standard CNI dosing and have been shown to be both safe and effective in the HIV+ KT population (15) (16) (17) .
Drug-drug interactions with PIs also pose a challenge to successful posttransplantation treatment of HCV in patients who are co-infected. Daclatasvir requires dose adjustment with PI-based regimens, whereas coadministration of elbasvir/grazoprevir or simeprevir and PIs are not recommended; use of ledipasvir/sofosbuvir with PIs requires monitoring for nephrotoxicity if patients are also taking tenofovir (18) . Avoidance of PI-based ART regimens will facilitate posttransplantation HCV therapy with direct-acting antivirals in co-infected KT recipients. Clinicians should also be cognizant of other important inhibitors of CYP3A4, beyond the protease inhibitors, that can lead to clinically significant alterations in pharmacokinetics in the HIV+ KT patient, including cobicistat (19, 20) .
The fact that PI-based regimens are associated with an increased risk of patient mortality is not entirely surprising. Although PI-based regimens are a potent means of establishing control over HIV replication and their use is associated with a rapid decline in viral loads, PIs have many deleterious side effects (21) . PIs have been implicated in the development of the metabolic syndrome and cardiovascular disease in HIV+ patients, in addition to de novo diabetes and hyperlipidemia (22) (23) (24) . It is reasonable to expect that these effects may be magnified in KT recipients, a population in which cardiovascular disease remains the primary cause of patient death (25, 26) .
This study has several strengths. It is the first national study to examine the effect of ART on posttransplantation outcomes for HIV+ KT using a novel linkage of the SRTR database to IMS Health pharmacy fills. Our cohort was large and represents 57% of the known HIV+ patients transplanted. Our use of registry data permits us to examine larger trends in HIV+ patient and allograft survival, and renders center-level practice variation less prominent. Our models are robust and enabled us to account for other known determinants of outcome in HIV+ KT such as HCV co-infection, donor quality, and maintenance immunosuppression. Furthermore, a previous single center report of 58 HIV+ KT confirms our findings; in that study 3-year patient-and death-censored allograft survival was 82% in the PItreated group as compared to 100% in the non-PI group, and no increase in acute rejection rates was observed (27) .
This study has several limitations inherent to the use of pharmacy clearing house and national transplant registry data. As we were not able to capture fills for 100% of patients in the SRTR dataset, this study does not capture the ART regimens of the entire HIV+ KT population. Furthermore, only 62.1% of our initial cohort of 535 had both a pre-and posttransplantation fill, limiting our ability to identify which patients were continued on PI-based ART after transplantation, but analyses limited to posttransplantation data were consistent with our main findings. With the availability of better-tolerated drugs, such as integrase inhibitors, which have fewer drug-drug interactions, PI-based regimens have fallen out of favor as first-line therapy for HIV in general and especially for use in HIV+ KT. However, these data are important as they underscore the need to transition all patients in whom HIV resistance profiles will permit changes off PIbased therapy and highlight the deleterious effects to both the patient and allograft of PI-based ART in the transplantation setting. Furthermore, although we would have expected an increased risk of acute rejection to explain at least part the inferior allograft survival observed in the PI cohort, we may have been insufficiently powered to detect such an effect. The SRTR dataset provides a comprehensive compendium of preand posttransplantation patient and donor characteristics; however, the incompleteness and inaccuracy of data reporting can challenge the utility and validity of this data source. For example, although data regarding acute rejection is provided in the dataset, we are unable to ascertain the type (antibody, cellular, or both) or severity of these rejection episodes. In addition, SRTR does not collect HIV-specific information including measures of viral control such as CD4 count or viral load, acquired immunodeficiency syndrome (AIDS)-defining illnesses or mode of HIV-infection acquisition. Despite these acknowledged limitations, this study is the first to describe national patient and allograft survival among HIV+ KT recipients according to ART regimen.
In conclusion, we present national outcomes for HIV+ KT demonstrating that PI-based regimens are associated with an increased risk of patient death and allograft loss in the posttransplantation setting. The deleterious effects of PIs on outcomes are not conclusively explained by acute rejection alone, and may reflect the cumulative effect of increased cardiovascular risk in the setting of trends toward higher acute rejection rates. In light of these data, it may be prudent to transition HIV+ KT candidates to a non-PI-containing regimen whenever possible. Critical evaluation of ART regimens by transplantation infectious diseases physicians should be a required part of the transplantation evaluation process for HIV+ KT candidates in order to maximize their posttransplantation survival.
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